Abstract 62P
Background
Sintilimab (Sin) helps the body to restore the anti-tumor response of T lymphocytes. However, in clinical use, the treatment process is more complicated due to adverse effects and different dosing regimens. It is not clear whether prebiotics (PREB) have a potentiating effect on Sin for lung adenocarcinoma, and this study intends to investigate the inhibitory effect, safety and possible mechanism of Sin combined with PREB on lung adenocarcinoma from animal experiments.
Methods
Lewis lung adenocarcinoma cells were inoculated into the right axilla of mice subcutaneously to prepare the Lewis lung cancer mouse model and treated in groups. The volume of transplanted tumors was measured, the histopathology of the liver and kidney of mice was observed by H&E staining, the levels of ALT, AST, UREA, CREA, WBC, RBC, and HGB in blood were analyzed biochemically; the ratio of T-cell subpopulations in blood, spleen, and bone marrow was detected by flow cytometry, the expression of PD-L1 in tumor tissue was detected by immunofluorescence staining, and 16S rRNA to analyze the diversity of fecal flora.
Results
Sin inhibited tumor growth and regulated immune cell homeostasis in lung adenocarcinoma mice, but liver and kidney histopathology showed different degrees of damage after Sin treatment, while the addition of PREB reduced liver and kidney damage in lung adenocarcinoma mice and promoted Sin's regulation of immune cells. In addition, the beneficial effects of Sin were associated with changes in intestinal flora diversity.
Conclusions
The mechanism by which Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice may be related to gut microbes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Chengdu Fifth People's Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
45P - Therapeutic potential of ISM8207: A novel QPCTL inhibitor, in triple-negative breast cancer and B-cell non-Hodgkin lymphoma
Presenter: Sujata Rao
Session: Poster session 09
46P - Effect of coadministration of antioxidant chlorophyllin with docetaxel on invasion and metastasis in triple-negative breast cancer in vivo/in vitro
Presenter: Ayse Burus
Session: Poster session 09
47P - An ozone delivery system by cisplatin prodrug self-assembling micelles combining microwave to sensitizing immune checkpoint inhibitor in triple-negative breast cancer
Presenter: Dan Zheng
Session: Poster session 09
48P - Non-steroid anti-inflammatory treatment enhances the efficacy of modulated electro hyperthermia on triple-negative breast cancer and melanoma cancer models in vivo
Presenter: Nino Giunashvili
Session: Poster session 09
49P - Circulating miRNA signatures to predict recurrence in patients with pathological complete response of triple-negative breast cancer
Presenter: Ana Julia de Freitas
Session: Poster session 09
50P - Application and mechanism of tarloxotinib in HER2-positive breast cancer
Presenter: Xinyi Shao
Session: Poster session 09
51P - Nanoengineered sonosensitive platelets for synergistically augmented sonodynamic breast tumour therapy by glutamine deprivation and cascading thrombosis
Presenter: Liqiang Zhou
Session: Poster session 09
53P - Treatment of cancer cells based on circulating tumor cell’s expression profile using off-label drugs
Presenter: Panagiotis Apostolou
Session: Poster session 09
54P - Enhanced oxidative phosphorylation of metastasis-initiating cells facilitates esophageal tumor cell seeding in lymph nodes
Presenter: Shanshan Li
Session: Poster session 09
55P - Transcriptional profiles of engineered T cells stimulated with different receptor structures and co-stimulatory domains
Presenter: Ungue Shin
Session: Poster session 09